Renasant Bio Secures $54.5M to Develop Treatments for ADPKD

Renasant Bio raises $54.5 million in seed funding to advance disease-modifying treatments for ADPKD.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here